Total Payments
$5,496
2024 Payments
$4,342
Companies
13
Transactions
36
Medicare Patients
3,702
Medicare Billing
$808,062
Payment Breakdown by Category
Education$2,596 (47.2%)
Food & Beverage$1,576 (28.7%)
Research$1,324 (24.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $2,596 | 6 | 47.2% |
| Food and Beverage | $1,576 | 22 | 28.7% |
| Unspecified | $1,324 | 8 | 24.1% |
Payments by Type
General
$4,172
28 transactions
Research
$1,324
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| INTUITIVE SURGICAL, INC. | $2,500 | 1 | $0 (2024) |
| United Therapeutics Corporation | $1,623 | 11 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $314.47 | 4 | $0 (2022) |
| Merck Sharp & Dohme LLC | $213.52 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $196.94 | 3 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $154.35 | 3 | $0 (2019) |
| AbbVie Inc. | $125.00 | 1 | $0 (2021) |
| Insmed, Inc. | $125.00 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $107.00 | 1 | $0 (2023) |
| Genentech USA, Inc. | $75.63 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,342 | 15 | INTUITIVE SURGICAL, INC. ($2,500) |
| 2023 | $331.09 | 8 | Merck Sharp & Dohme LLC ($177.34) |
| 2022 | $246.52 | 3 | Paratek Pharmaceuticals, Inc. ($125.05) |
| 2021 | $300.76 | 3 | Paratek Pharmaceuticals, Inc. ($175.76) |
| 2020 | $13.66 | 1 | Paratek Pharmaceuticals, Inc. ($13.66) |
| 2019 | $136.34 | 4 | Genentech USA, Inc. ($75.63) |
| 2018 | $126.28 | 2 | Actelion Pharmaceuticals US, Inc. ($114.97) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/05/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $149.19 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $87.64 | General |
| 07/18/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/20/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Respiratory | ||||||
| 04/30/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $119.28 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/25/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $2,500.00 | General |
| Category: SURGERY | ||||||
| 01/25/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $125.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/24/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $609.44 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/24/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $234.05 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/24/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $206.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 11/29/2023 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $19.81 | General |
| 08/24/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $107.00 | General |
| 08/21/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $86.83 | General |
| 07/17/2023 | United Therapeutics Corporation | TYVASO (Drug), REMODULIN | Food and Beverage | In-kind items and services | $30.13 | General |
| Category: PAH | ||||||
| 06/02/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX, TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: RESPIRATORY | ||||||
| 06/01/2023 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $19.81 | General |
| 06/01/2023 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $19.81 | General |
| 05/20/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $31.08 | General |
| 04/27/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $87.97 | General |
| 04/22/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $125.05 | General |
| Category: ANTIBIOTIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | United Therapeutics Corporation | $1,324 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 761 | 1,450 | $284,226 | $138,989 |
| 2022 | 14 | 795 | 1,506 | $331,818 | $157,936 |
| 2021 | 16 | 967 | 1,807 | $452,250 | $212,606 |
| 2020 | 17 | 1,179 | 2,468 | $636,262 | $298,531 |
Total Patients
3,702
Total Services
7,231
Medicare Billing
$808,062
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 103 | 311 | $116,936 | $50,585 | 43.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 136 | 345 | $51,750 | $31,264 | 60.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 121 | 226 | $33,900 | $19,683 | 58.1% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 26 | 111 | $21,090 | $13,286 | 63.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $8,200 | $4,651 | 56.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 72 | $7,920 | $4,513 | 57.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 64 | 75 | $7,500 | $3,176 | 42.4% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 64 | 76 | $7,600 | $3,100 | 40.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 22 | $6,270 | $2,831 | 45.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 68 | 80 | $10,400 | $2,285 | 22.0% |
| 76604 | Ultrasound scan of chest | Office | 2023 | 20 | 37 | $7,400 | $1,509 | 20.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 22 | $2,860 | $1,317 | 46.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 29 | 32 | $2,400 | $788.71 | 32.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 154 | 446 | $167,696 | $76,606 | 45.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 174 | 430 | $64,500 | $33,856 | 52.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 103 | 178 | $26,700 | $16,455 | 61.6% |
| 99310 | Follow-up nursing facility visit per day, typically 35 minutes | Facility | 2022 | 18 | 62 | $11,780 | $6,343 | 53.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $8,400 | $4,719 | 56.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 28 | $7,980 | $4,429 | 55.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 65 | $7,150 | $4,141 | 57.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 51 | 56 | $5,600 | $2,447 | 43.7% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 51 | 56 | $5,600 | $2,337 | 41.7% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 18 | 26 | $4,732 | $2,182 | 46.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 56 | 61 | $7,930 | $1,832 | 23.1% |
| 76604 | Ultrasound scan of chest | Office | 2022 | 18 | 26 | $5,200 | $1,102 | 21.2% |
About Dr. Alfredo Arauco Brown, M.D
Dr. Alfredo Arauco Brown, M.D is a Pulmonary Disease healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2010. The National Provider Identifier (NPI) number assigned to this provider is 1841503513.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alfredo Arauco Brown, M.D has received a total of $5,496 in payments from pharmaceutical and medical device companies, with $4,342 received in 2024. These payments were reported across 36 transactions from 13 companies. The most common payment nature is "Education" ($2,596).
As a Medicare-enrolled provider, Arauco Brown has provided services to 3,702 Medicare beneficiaries, totaling 7,231 services with total Medicare billing of $808,062. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Weslaco, TX
- Active Since 07/22/2010
- Last Updated 12/07/2016
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1841503513
Products in Payments
- Da Vinci Surgical System (Device) $2,500
- TYVASO (Drug) $1,623
- NUZYRA (Drug) $314.47
- Arikayce (Drug) $125.00
- DALVANCE (Drug) $125.00
- Esbriet (Biological) $75.63
- WINREVAIR (Biological) $36.18
- ILLUMISITE (Device) $33.50
- OPSUMIT (Drug) $27.56
- AREXVY (Drug) $16.62
- UPTRAVI (Drug) $11.82
- LONHALA MAGNAIR (Drug) $11.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.